



File No. U-25/12/NSQ/2023-MedV(E-178406)/324 दिनांक: 14-10-2026

सेवा में,

Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents - All ESIC Hospitals,
Directors, ESI Scheme, All States

NSQ-12/2026

Subject: **Declaration of Drug "Not of Standard Quality" on Testing - reg**

Sir/Madam

It is hereby informed that the Drug/item has been reported as "Not of Standard Quality". The details of the drug reported NSQ is given below:

Sample taken from Premises	Name of the Firm (M/s)	Item Name / Brand Name	RC No/ Item No/ Page No	Batch No. / DO M/ D OE	Name of the Laboratory/ Report No. & Date	Reason of NSQ
ESIC Hospital, Tinsukia	Alpa Laboratories Ltd.	Paracetamol Tablets IP 650 mg	1592024	Batch No. - TV6122 DOM: 08/26 DOE: 07/28	The Government Analyst, Jalukbari, Guwahati SDTL/L/SB/2026/1536 Dated-30/09/2026	The sample does not conform to I.P. with respect to the test for "Dissolution" of Paracetamol Tablets IP 650 mg (Copy enclosed).

In context to above, it is directed to:

1. Medical Store to immediately withdrawn stock from respective sub-stores/Dispensaries/patient care area.
2. Medical Store to immediately write a letter to vendor for replacement of stock with another batch, within 15 days or to pick up stock and return the payment made other process of risk

purchase to be initiated and recover cost of testing (if any) from the vendor.

3. Stop use of the batch of the above-mentioned item immediately which has been reported as "Not of Standard Quality".
4. Initiate action as per relevant clause of Terms & Conditions of respective DG-ESIC Tender Enquiry/RC.
5. Maintained record of action taken at in respective user units.

यह चिकित्सा आयुक्त (प्रोक्योरमेंट) के अनुमोदन से जारी किया जाता है।

संलग्नक: उपरोक्त

भवदीय,

Digitally signed by
Sanjiv Kochhar
Date: 15-10-2026
16:16:45

उप चिकित्सा आयुक्त (दर अनुबंध)


प्रतिलिपि:

1. The Drug Controller General of India, CDSCO, CIG Road, New Delhi-110002 (dci@nic.in).
2. Office of Assistant Drug Controller (I), Central Drug Standard Control Organization, Sub-Zonal Office, Regional Drugs Testing Laboratory Campus, Six Mile, Panjabari Road, Guwahati-781022, AP, (E-mail: subzone.guwahati@cdsco.nic.in)
- 3 Alpa Laboratories Ltd., 33/2, A.B. Road, Pigdamber- 453446, Indore (M.P)
(Email: tenders@alpalabs.in)
- ✓ 4. Website Content Manager with request for uploading on ESIC website.
5. Guard file



सत्यमेव जयते

GOVERNMENT OF ASSAM
OFFICE OF THE INSPECTOR OF DRUGS:: TINSUKIA
C/O THE OFFICE OF JOINT DIRECTOR OF HEALTH SERVICES,
TINSUKIA-786125
Email: ldtinsukia@gmail.com



NO. ID /TSK/ **670** /
From :

Dated Tinsukia the 6th day of October -2026

The Inspector of Drugs, Tinsukia

✓ To : The Medical Superintendent
E.S.I.C Hospital, Bordoloi Nagar, Tinsukia

Sub : NSQ report of "Paracetamol Tablets IP 650 mg, Batch No. TV6122, Mfg. Date: 08/2026, Exp. Date: 07/2028, manufactured by ALPA LABORATORIES LTD, 33/2, A.B.Road, PIGDAMBER-453446, INDORE (MP)- reg.

Sir/Madam,

With reference to the subject cited above, I am forwarding herewith one Test Report in Form-13 (Report No. SDTL/L/SB/2026/1536) received from the Government Analyst, State Drugs Testing Laboratory, Jalukbari, Guwahati-14. The report declares **Paracetamol Tablets IP 650 mg, Batch No. TV6122**, Mfg. Date: 08/2026, Exp. Date: 07/2028, manufactured by ALPA LABORATORIES LTD, 33/2, A.B.Road, PIGDAMBER-453446, INDORE(MP), as **Not of Standard Quality (NSQ)**.

You are therefore requested to **immediately stop all distribution** of the aforementioned batch and arrange to **withdraw and recall** the distributed stock of the said batch from all sources without delay.

Further, you are requested to furnish the following information within 7(seven) days from the date of receipt of this letter:

1. Total quantity of the drug received, along with invoice details and dates of receipt.
2. Name and full address of the supplier/manufacturer from whom the drug was procured.
3. Present stock position of the aforesaid batch currently held in your premises.
4. Any other withdrawal protocols (if any).

This is for your kind information and **immediate necessary action**.

Inspector of Drugs, Tinsukia

Memo. NO. ID /TSK/ /
Copy for information to-

Dated Tinsukia the 6th day of October -2026

1. The District Commissioner, Tinsukia
2. The Drugs Controller (i/c) LA, Hengrababi, Guwahati-36

Inspector of Drugs, Tinsukia



STATE DRUGS TESTING LABORATORY
IN-CHARGE, GOVERNMENT ANALYST, JALUKBARI, GUWAHATI-781014
Email: sdtlguwahati@gmail.com

FORM 13
(See Rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25 (1) OF THE DRUGS & COSMETICS ACT, 1940

1. Name of Inspector from whom received : **DIPU KONWAR**
INSPECTOR OF DRUGS
TINSUKIA, ASSAM
2. Serial No. and date of Inspector's memorandum : **ID/TSK/DK//Sample/77/26, 17/09/2026**
3. Number of Sample : **60 TABLETS**
4. Date of receipt : **22/09/2026**
5. Names of drugs purporting to be contained in the sample: **PARACETAMOL TABLETS IP 650 MG**

Lab. Sample No.	Report No.	Batch No.	Date of Mfg.	Date of Exp.	Mfg. By
AL/L/26/2043	SDTL/L/SB/2026/1536	TV6122	08/2026	07/2028	ALPA LABORATORIES LTD. 33/2, A.B. ROAD, PIGDAMBER-453446, INDORE (MP)

6. Condition of Seals : Seals were intact & identical to the
[on the packet or on portion of sample or container] specimen impression of the seal received
from Drugs Inspector.

7. Result of test or analysis with protocols or test analysis applied: Please see below
Date of Testing: From: 25-09-2026 to 29-09-2026

COMPOSITION: Each uncoated tablet contains: **PARACETAMOL IP 650 MG**

PROTOCOL APPLIED: I.P. 2026

Sl. No.	Test Name	Result	Limits
1.	Description	White colour oval shaped uncoated tablet break line on one side & plain on other side	NA
2.	Identification	After cooling no ppt is formed & in addition of 0.0167 M potassium dichromate a violet colour is developed	NA
3.	Average Weight	813.77 MG	As per IP
4.	Dissolution	52.82% to 81.40%	NLT 80%
5.	Related substances	No peak for 4-aminophenol is eluted	NMT 0.1%

ASSAY:

Sl. No	Ingredient Name	Claim	Found	% of Claim	Limit	Procedure/ Method
1.	Paracetamol IP	650 MG	652.41 MG	100.37%	95.% to 105%	IP 2026

In the opinion of the undersigned the sample referred to above (is of standard/is not of standard) quality for the test of (Average Weight / Dissolution / Assay) as defined in the Drugs and Cosmetics Act, 1940, and Rules thereunder for the reasons given below: -

The sample does not conform to I.P. with respect to the above tests only.

Date: 30-09-2026

Government Analyst.

Government Analyst
State Drugs Testing Laboratory
Jalukbari, Guwahati-14, Assam